Bio-Techne(TECH)
Search documents
Bio-Techne(TECH) - 2024 Q2 - Earnings Call Transcript
2024-02-01 20:42
Bio-Techne Corporation (NASDAQ:TECH) Q2 2024 Earnings Conference Call February 1, 2024 9:00 AM ET Company Participants David Clair - Vice President, Investor Relations Charles Kummeth - Former Chief Executive Officer and Current Senior Advisor Kim Kelderman - Chief Executive Officer James Hippel - Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners Jacob Johnson - Stephens Inc. Dan Arias - Stifel Financial Corp Patrick Donnelly - Citi Dan Leonard - UBS Matthew Larew - Willia ...
Bio-Techne(TECH) - 2024 Q1 - Quarterly Report
2023-11-07 21:35
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other ...
Bio-Techne(TECH) - 2024 Q1 - Earnings Call Transcript
2023-10-31 20:08
Bio-Techne Corporation (NASDAQ:TECH) Q1 2024 Earnings Conference Call October 31, 2023 9:00 AM ET Company Participants David Clair - Vice President-Investor Relations Charles Kummeth - Chief Executive Officer James Hippel - Chief Financial Officer Kim Kelderman - Chief Operating Officer. Conference Call Participants Puneet Souda - SVB Securities Patrick Donnelly - Citi Catherine Schulte - Baird Matthew Larew - William Blair Alex Nowak - Craig-Hallum Paul Knight - KeyBanc Justin Bowers - Deutsche Bank Operat ...
Bio-Techne(TECH) - 2023 Q4 - Annual Report
2023-08-23 20:30
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jurisdiction ...
Bio-Techne(TECH) - 2023 Q4 - Earnings Call Transcript
2023-08-08 19:49
Bio-Techne Corporation (NASDAQ:TECH) Q4 2023 Earnings Conference Call August 8, 2023 9:00 AM ET Company Participants David Clair – Vice President-Investor Relations Chuck Kummeth – Chief Executive Officer Jim Hippel – Chief Financial Officer Will Geist – President-Protein Sciences Segment Conference Call Participants Puneet Souda – Leerink Partners Patrick Donnelly – Citi Jacob Johnson – Stephens Dan Arias – Stifel Dan Leonard – Credit Suisse Catherine Schulte – Baird Operator Good morning, and welcome to t ...
Bio-Techne(TECH) - 2023 Q3 - Quarterly Report
2023-05-08 20:30
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other jur ...
Bio-Techne(TECH) - 2023 Q3 - Earnings Call Transcript
2023-05-03 19:39
Bio-Techne Corporation (NASDAQ:TECH) Q3 2023 Earnings Conference Call May 3, 2023 9:00 AM ET Company Participants David Clair – Vice President-Investor Relations Chuck Kummeth – Chief Executive Officer Jim Hippel – Chief Financial Officer Conference Call Participants Puneet Souda – SVB Securities Jacob Johnson – Stephens Dan Arias – Stifel Dan Leonard – Credit Suisse Patrick Donnelly – Citi Catherine Schulte – Baird Justin Bowers – Deutsche Bank Alex Nowak – Craig-Hallum Operator Good day, and welcome to th ...
Bio-Techne(TECH) - 2023 Q2 - Quarterly Report
2023-02-07 21:30
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other ...
Bio-Techne(TECH) - 2023 Q2 - Earnings Call Transcript
2023-02-02 16:51
Bio-Techne Corporation (NASDAQ:TECH) Q2 2023 Earnings Conference Call February 2, 2023 9:00 AM ET Company Participants David Clair - Vice President of Investor Relations Chuck Kummeth - Chief Executive Officer Jim Hippel - Chief Financial Officer Conference Call Participants Puneet Souda - SVB Securities Jacob Johnson - Stephens Dan Arias - Stifel Dan Leonard - Credit Suisse Catherine Schulte - Baird Patrick Donnelly - Citi Justin Bowers - Deutsche Bank Operator Good morning, and welcome to the Bio-Techne E ...
Bio-Techne(TECH) - 2023 Q1 - Earnings Call Transcript
2022-11-01 16:55
Bio-Techne Corporation (NASDAQ:TECH) Q1 2023 Earnings Conference Call November 1, 2022 9:00 AM ET Company Participants Chuck Kummeth - President, Chief Executive Officer Jim Hippel - Executive Vice President, Chief Financial Officer David Clair - Vice President, Investor Relations Conference Call Participants Puneet Souda - SVB Securities Dan Arias - Stifel Dan Leonard - Credit Suisse Anna - Stephens Alex Nowak - Craig Hallum Catherine Schulte - Baird Patrick Donnelly - Citi Operator Good morning and wel ...